• Johnson & Johnson announced three clinical analyses showing lower mortality with Impella-supported high-risk coronary procedures than reported in CHIP-BCIS3.
• The real-world and observational analyses covered 1,379 U.S. and European patients; results will be presented at TCT Nov. 1-3, 2026.
• Findings suggest patient selection, timing of support and post-procedure care may influence outcomes.
• The ongoing PROTECT IV randomized controlled trial is expected to report results in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 202611010800BIZWIRE_USPR_____20261101_BW267685) on November 01, 2026, and is solely responsible for the information contained therein.